{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:32:19Z","timestamp":1785522739733,"version":"3.56.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Trifluridine\/tipiracil (FTD\/TPI) is effective for advanced colorectal and gastric cancers; however, limited real-world data exist on physician and patient experiences with non-hematologic toxicities such as nausea, anorexia, and fatigue. We investigated the real-world incidence and management of these side effects from both perspectives. A web-based questionnaire survey was conducted among physicians experienced in prescribing FTD\/TPI and patients with colorectal or gastric cancer who were receiving or had received these medications. Patients reported non-hematologic toxicities\u2012fatigue, anorexia, nausea, diarrhea, and vomiting\u2012more frequently and earlier than physicians anticipated. Fatigue and anorexia were the most distressing side effects for patients and the most challenging for physicians to manage. Discrepancies existed between physicians and patients regarding communication and side-effect management strategies. Although nausea and vomiting were manageable with antiemetics, clear management methods for fatigue and anorexia have not been established. Patients valued detailed explanations about medication administration, non-hematologic side effects, and costs more than physicians recognized. In FTD\/TPI therapy, a discrepancy exists between physicians\u2019 and patients\u2019 perceptions of non-hematologic toxicities, which may pose challenges in effective symptom management. Symptoms such as fatigue and anorexia appear to be less adequately addressed, highlighting the need for continued efforts to improve management strategies.<\/jats:p>","DOI":"10.1038\/s41598-026-50912-5","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:14:33Z","timestamp":1779434073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Web questionnaire survey of physicians and patients on the side effects of trifluridine\/tipiracil"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-2335","authenticated-orcid":false,"given":"Takako Eguchi","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Okude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Tone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Oshika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Yokomizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"50912_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ctrv.2015.06.001","volume":"41","author":"H-J Lenz","year":"2015","unstructured":"Lenz, H.-J., Stintzing, S. & Loupakis, F. TAS-102, a novel antitumor agent: A review of the mechanism of action. Cancer Treat. Rev. 41, 777\u2013783 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"50912_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"50912_CR3","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657\u20131667 (2023).","journal-title":"N. Engl. J. Med."},{"key":"50912_CR4","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 1437\u20131448 (2018).","journal-title":"Lancet Oncol."},{"key":"50912_CR5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara, H. et al. 2023 Japan society of clinical oncology clinical practice guidelines update for antiemesis. Int. J. Clin. Oncol. 29, 873\u2013888 (2024).","journal-title":"Int. J. Clin. Oncol."},{"key":"50912_CR6","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh, P. J. et al. Antiemetics: ASCO guideline update. J. Clin. Oncol. 38, 2782\u20132797 (2020).","journal-title":"J. Clin. Oncol."},{"key":"50912_CR7","first-page":"53","volume":"32","author":"K Jordan","year":"2023","unstructured":"Jordan, K. et al. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC\/ESMO consensus recommendation. Support. Care Cancer 32, 53 (2023).","journal-title":"Support. Care Cancer"},{"key":"50912_CR8","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1002\/pon.3268","volume":"22","author":"K Nozawa","year":"2013","unstructured":"Nozawa, K. et al. Quantitative assessment of appearance changes and related distress in cancer patients. Psychooncology 22, 2140\u20132147 (2013).","journal-title":"Psychooncology"},{"key":"50912_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJMp0911494","volume":"362","author":"E Basch","year":"2010","unstructured":"Basch, E. The missing voice of patients in drug-safety reporting. N. Engl. J. Med. 362, 865\u2013869 (2010).","journal-title":"N. Engl. J. Med."},{"key":"50912_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(16)00038-3","volume":"17","author":"G Thanarajasingam","year":"2016","unstructured":"Thanarajasingam, G. et al. Longitudinal adverse event assessment in oncology clinical trials: The toxicity over time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol. 17, 663\u2013670 (2016).","journal-title":"Lancet Oncol."},{"key":"50912_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/EDBK_159514","volume":"35","author":"PG Kluetz","year":"2016","unstructured":"Kluetz, P. G., Chingos, D. T., Basch, E. M. & Mitchell, S. A. Patient-reported outcomes in cancer clinical trials: Measuring symptomatic adverse events with the national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Am. Soc. Clin. Oncol. Educ. Book 35, 67\u201373 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"50912_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamaoncol.2019.5566","volume":"6","author":"TM Atkinson","year":"2020","unstructured":"Atkinson, T. M. et al. Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials. JAMA Oncol. 6, 437\u2013439 (2020).","journal-title":"JAMA Oncol."},{"key":"50912_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.27403","volume":"8","author":"Y Kikawa","year":"2025","unstructured":"Kikawa, Y. et al. Electronic patient-reported outcomes with vital sign monitoring during trastuzumab deruxtecan therapy: The PRO-DUCE randomized clinical trial. JAMA Netw. Open 8, e2527403 (2025).","journal-title":"JAMA Netw. Open"},{"key":"50912_CR14","first-page":"279","volume":"49","author":"S Belcher","year":"2022","unstructured":"Belcher, S. et al. ONS guidelines\u2122 to support patient adherence to oral anticancer medications. Oncol Nurs Forum. 49, 279\u2013295 (2022).","journal-title":"Oncol Nurs Forum."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50912-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50912-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50912-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:18:35Z","timestamp":1785518315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50912-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50912"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50912-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Takako Eguchi Nakajima received research funding from KBBM, Inc. and Takeda Pharmaceutical Co., Ltd. Ryota Okude is an employee of Taiho Pharmaceutical Co., Ltd. Takuma Tone is an employee of Taiho Pharmaceutical Co., Ltd. Ayako Oshika is an employee of Taiho Pharmaceutical Co., Ltd. Ayako Yokomizo declares no potential conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and applicable national ethical guidelines. Ethical approval was granted by Mins, a certified non-profit organization (NPO) functioning as an external ethics review committee (IRB No. MINS-REC-230222). Informed consent was obtained from all individual participants included in the study. Compensation was provided to both physicians and patients who participated in this study. All participants reviewed the study information and provided informed consent prior to participation in the survey.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"23366"}}